Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open-Label Extension Study to Assess Long-Term Safety and Tolerability of Enobosarm (GTx 024) in Postmenopausal Women With Stress Urinary Incontinence

NCT03566290 is registered in ClinicalTrials.gov with GTx as lead sponsor.

NCT NCT03566290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03566290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open-Label Extension Study to Assess Long-Term Safety and Tolerability of Enobosarm (GTx 024) in Postmenopausal Women With Stress Urinary Incontinence
Lead sponsor
GTx
Phase
Phase 2
Overall status
Withdrawn
Start date
June 28, 2018
Completion date
September 21, 2018
Enrollment
0 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

stress urinary incontinence